No Direct Comparison Exists Between Clesrovimab and Nirsevimab in Clinical Trials
Clesrovimab has never been directly compared to nirsevimab in any clinical trial. The pivotal trials for clesrovimab used placebo controls (in healthy infants) or palivizumab controls (in high-risk infants), not nirsevimab 1, 2.
What the Clinical Trial Evidence Actually Shows
Clesrovimab's Trial Design
The phase 2b/3 trial (Trial 004) evaluated clesrovimab against placebo, not nirsevimab 1. In this study:
- RSV-associated hospitalization reduction: 90.9% (95% CI = 76.2%–96.5%) compared to placebo
- Only 5 of 2,398 infants (0.2%) receiving clesrovimab were hospitalized for RSV versus 27 of 1,201 (2.2%) receiving placebo 1
The phase 3 trial in high-risk infants (Trial 007) compared clesrovimab to palivizumab, not nirsevimab, and showed similar hospitalization rates between the two groups 1.
Why This Matters Clinically
The ACIP explicitly states that clesrovimab and nirsevimab are considered equivalent alternatives 1. The 2025 ACIP guidelines recommend both as interchangeable options, with selection based on parent preference, product availability, and timing—not on superior efficacy of one over the other 1.
Indirect Comparisons and Modeling Studies
Since no head-to-head trials exist, researchers have attempted indirect comparisons through modeling:
- One cost-effectiveness analysis suggested nirsevimab may prevent more RSV-LRTD events than clesrovimab, but this depends heavily on assumed duration of protection for clesrovimab (100-150 days) 3, 4
- Another modeling study found clesrovimab cost-saving compared to nirsevimab, but again relied on post-hoc efficacy adjustments 5
- A comprehensive review concluded that when accounting for differences in study populations and endpoint definitions, both agents offer broadly comparable protection against severe RSV disease 6
Critical Limitations of These Comparisons
These modeling studies are not clinical trial evidence. They involve:
- Different trial populations (clesrovimab studied infants ≥29 weeks GA; nirsevimab included more premature infants)
- Different endpoint definitions across trials
- Assumptions about duration of protection that may not reflect real-world performance
- Post-hoc statistical adjustments to align non-comparable data 5, 7
Clinical Bottom Line
You cannot say clesrovimab reduced hospitalization "compared to nirsevimab" because they were never tested against each other. What you can say:
Both reduce RSV hospitalizations by approximately 80-90% compared to no prophylaxis based on their respective placebo-controlled trials 1, 8
ACIP considers them therapeutically equivalent and recommends choosing based on practical factors, not efficacy differences 1
Real-world effectiveness data exists for nirsevimab (showing 70-80% protection against hospitalization), while clesrovimab lacks such data as the newest agent 1, 6
Safety profiles are comparable between both agents, with similar rates of mild injection-site reactions and no significant safety concerns 1, 6
Practical Prescribing Guidance
When choosing between these agents, consider:
- Product availability in your region (nirsevimab has been available longer)
- Dosing simplicity: clesrovimab uses one 105 mg dose regardless of weight; nirsevimab requires weight-based dosing (50 mg for <5 kg, 100 mg for ≥5 kg) 1
- Cost and insurance coverage in your practice setting
- Parent preference after discussing both options
The absence of head-to-head trial data means clinical equipoise exists between these two agents based on current evidence 1, 6.